Every Hayes clinical evidence report is developed by experienced teams that have been trusted by healthcare decision makers since 1989. Here is a sampling of our content that is being used every day to inform defensible, evidence-based decisions by payers and providers.
Not all reports are available for public preview. For more information, please contact us.
Breyanzi (lisocabtagene maraleucel [liso-cel]) is an autologous chimeric antigen receptor (CAR) T-cell therapy, a novel type of immunotherapy in which a patient’s own immune cells are genetically re-programmed to target and attack cancer cells. It is indicated for the treatment of adult patients with relapsed or refractory (R/R) large B-cell lymphoma after 2 or more lines of …
Sutimlimab is an intravenous monoclonal antibody targeting complement component 1s (C1s) for the treatment of cold agglutinin disease.
Sotorasib (AMG 510) is an investigational oral KRAS G12C inhibitor designed to block the abnormal proliferative action of mutant KRAS protein. It is under investigation for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with KRAS G12C mutation.
This report evaluates the analytical validity, clinical validity, and clinical utility of the Prospera test.
Oxlumo (lumasiran) is a subcutaneously injected, HAO1-directed small interfering ribonucleic acid (siRNA) indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients. Dosing is weight-based; for children weighing less than 10 kg, the recommended maintenance dose is 3 mg/kg once monthly. Dosing for individua…
This report evaluates the analytical validity, clinical validity, and clinical utility of the Afirma Genomic Sequencing Classifier (Veracyte Inc.) test.
Focus of the Report: This report focuses on pattern electroretinography (PERG) for the diagnosis of glaucoma.
Technology Description: Early diagnosis of glaucoma can reduce the risk of irreversible vision loss and blindness. Electroretinography (ERG) is a minimally invasive procedure that provides an objective assessment of retinal function. PERG is a …
The Portable Neuromodulation Stimulator (PoNS) device is a portable neuromodulation stimulator for short-term treatment of gait deficit due to mild to moderate symptoms from multiple sclerosis for use by prescription only as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and older.
Finerenone is an investigational nonsteroidal, selective mineralocorticoid receptor antagonist for treatment of patients with chronic kidney disease and type 2 diabetes.
Focus of the Report: This report focuses on Aquablation therapy for the treatment of lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH).
Technology Description: Aquablation therapy is a minimally invasive procedure that ablates overgrown prostatic tissue in order to restore patency to the urethral passageway. High-veloci…